MOB2 and central nervous system cancer: To assess the expression of MOB2 in glioma clinical samples, we performed an immunohistochemical (IHC) analysis on normal brain tissues, low grade gliomas (LGGs, WHO grade I and II gliomas, n = 16) and glioblastoma (GBMs, WHO grade IV gliomas, n = 19) samples.